Adiponectin receptor 1 expression is associated with carotid plaque stability

Neurology India

Volumn 61, Issue 3, 2013, Pages 249-253

  Takeuchi, Satoru ^a   Wada, Kojiro ^a   Uozumi, Yoichi ^b   Otani, Naoki ^a   Osada, Hideo ^a   Nagatani, Kimihiro ^a   Mori, Kentaro ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b Kamiiida Daiichi General Hospital   (Japan)

Author keywords

Adiponectin receptor; atherosclerosis; carotid artery stenosis; carotid plaque; stability

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2;

AGED; ARTICLE; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION;

AGED; CAROTID STENOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, ADIPONECTIN;

EID: 84883147074     PISSN: 00283886     EISSN: 19984022     Source Type: Journal    
DOI: 10.4103/0028-3886.115063     Document Type: Article

References (33)

1. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: The Oxford plaque study. Circulation 2006; 113: 2320-8.
2. Rothwell PM, Gibson R, Warlow CP. Interrelation between plaque surface morphology and degree of stenosis on carotid angiograms and the risk of ischemic stroke in patients with symptomatic carotid stenosis. On behalf of the European Carotid Surgery Trialists' Collaborative Group. Stroke 2000; 31: 615-21.
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I. Circulation 2003; 108: 1664-72.
4. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
5. Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 1996; 16: 4-11.
6. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95.
7. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9.
8. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-9.
9. Zhu W, Cheng KK, Vanhoutte PM, Lam KS, Xu A. Vascular effects of adiponectin: Molecular mechanisms and potential therapeutic intervention. Clin Sci (Lond) 2008; 114: 361-74.
10. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun 2004; 314: 151-8.
11. Tian L, Luo N, Zhu X, Chung BH, Garvey WT, Fu Y. Adiponectin-AdipoR1/2- APPL1 signaling axis suppresses human foam cell formation: Differential ability of AdipoR1 and AdipoR2 to regulate inflammatory cytokine responses. Atherosclerosis 2012; 221: 66-75.
12. Tian L, Luo N, Klein RL, Chung BH, Garvey WT, Fu Y. Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 2009; 202: 152-61.
13. Li D, Wang D, Wang Y, Ling W, Feng X, Xia M. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice. J Biol Chem 2010; 285: 33499-509.
14. Gil-Campos M, Cañete RR, Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin Nutr 2004; 23: 963-74.
15. Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: The new endocrine organ? A review article. Dig Dis Sci 2009; 54: 1847-56.
16. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 11-8.
17. Nakamura Y, Shimada K, Fukuda D, Shimada Y, Ehara S, Hirose M, et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-33.
18. Otake H, Shite J, Shinke T, Watanabe S, Tanino Y, Ogasawara D, et al. Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome. Am J Cardiol 2008; 101: 1-7.
19. Kunita E, Yamamoto H, Kitagawa T, Ohashi N, Utsunomiya H, Oka T, et al. Association between plasma high-molecular-weight adiponectin and coronary plaque characteristics assessed by computed tomography angiography in conditions of visceral adipose accumulation. Circ J 2012; 76: 1687-96.
20. Sawada T, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, et al. Low plasma adiponectin levels are associated with presence of thin-cap fibroatheroma in men with stable coronary artery disease. Int J Cardiol 2010; 142: 250-6.
21. Gardener H, Sjoberg C, Crisby M, Goldberg R, Mendez A, Wright CB, et al. Adiponectin and carotid intima-media thickness in the northern Manhattan study. Stroke 2012; 43: 1123-5.
22. Dullaart RP, Kappelle PJ, Dallinga-Thie GM. Carotid intima media thickness is associated with plasma adiponectin but not with the leptin: Adiponectin ratio independently of metabolic syndrome. Atherosclerosis 2010; 211: 393-6.
23. Liapis CD, Bell PR, Mikhailidis D, Sivenius J, Nicolaides A, Fernandes e Fernandes J, et al. ESVS Guidelines Collaborators. ESVS guidelines. Invasive treatment for carotid stenosis: Indications, techniques. Eur J Vasc Endovasc Surg 2009; 37 (4 Suppl): 1-19.
24. North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke 1991; 22: 711-20.
25. Cai JM, Hatsukami TS, Ferguson MS, Small R, Polissar NL, Yuan C. Classification of human carotid atherosclerotic lesions with in vivo multicontrast magnetic resonance imaging. Circulation 2002; 106: 1368-73.
26. Gao T, Zhang Z, Yu W, Zhang Z, Wang Y. Atherosclerotic carotid vulnerable plaque and subsequent stroke: A high-resolution MRI study. Cerebrovasc Dis 2009; 27: 345-52.
27. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery plaque: Current imaging methods and new perspectives. Stroke 2005; 36: 2764-72.
28. Li L, Cai XJ, Feng M, Rong YY, Zhang Y, Zhang M. Effect of adiponectin over expression on stability of preexisting plaques by inducing prolyl-4-hydroxylase expression. Circ J 2010; 74: 552-9.
29. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: State of the art? Am J Physiol Heart Circ Physiol 2007; 292: H1655-63.
30. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
31. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001; 104: 503-16.
32. Ishii N, Matsumura T, Kinoshita H, Motoshima H, Kojima K, Tsutsumi A, et al. Activation of AMP-activated protein kinase suppresses oxidized low-density lipoprotein-induced macrophage proliferation. J Biol Chem 2009; 284: 34561-9.
33. O'Leary VB, Jorett AE, Marchetti CM, Gonzalez F, Phillips SA, Ciaraldi TP, et al. Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults. Am J Physiol Endocrinol Metab 2007; 293: E421-7.